China Resources Double-Crane Pharmaceutical Co.,Ltd. (SHA:600062)

China · Delayed Price · Currency is CNY

16.00

-0.42 (-2.56%)

Aug 14, 2026, 3:00 PM CST

-21.10% (1Y)

Market Cap	16.52B -20.7%
Revenue (ttm)	10.73B -3.7%
Net Income	1.63B +0.2%
EPS	1.57 -0.4%
Shares Out	1.03B
PE Ratio	10.20
Forward PE	9.44
Dividend	0.48 (2.99%)
Ex-Dividend Date	Jul 28, 2026

Volume	13,916,731
Open	16.42
Previous Close	16.42
Day's Range	15.97 - 16.44
52-Week Range	15.29 - 20.70
Beta	-0.07
Analysts	Strong Buy
Price Target	25.33 (+58.31%)
Earnings Date	Aug 22, 2026

About SHA:600062

China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a pharmaceutical company in the People’s Republic of China. The company offers pharmaceutical products for blood pressure and sugar, injections, lipid-lowering, pediatrics, nephrology, API, pharmaceutical, psychiatry/neurology, inflammation, anticoagulation, oncology, women's health, anesthesia, and analgesia. The company was founded in 1939 and is headquartered in Beijing, the People’s Republic of China. China Resources Double-Crane Pharmaceutical Co.,Ltd. operates as a subsidiar... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1939

Employees 13,184

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600062

Full Company Profile

Financial Performance

In 2025, SHA:600062's revenue was 11.00 billion, a decrease of -1.88% compared to the previous year's 11.21 billion. Earnings were 1.65 billion, an increase of 1.18%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 600062 stock is "Strong Buy." The 12-month stock price target is ¥25.33, which is an increase of 58.31% from the latest price.

Price Target

¥25.33

(58.31% upside)

Analyst Consensus: Strong Buy

Stock Forecasts